Akebia Therapeutics (AKBA) Reports Q4 results

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 Revenue for the quarter at $56.2 million versus the consensus estimate of $55.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00